SCHEMBL7301948

SCHEMBL7301948

O=c1ccc(-c2c(-c3ccccc3)nn3ccccc23)nn1Cc1nnn[nH]1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.59
IGF1R P08069 2/20 0.49
MAPK1 P28482 5/20 0.44
MAPK14 Q16539 2/20 0.44
MAPK3 P27361 1/20 0.44
PDE3A Q14432 2/20 0.38
PDE4B Q07343 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
AKT1 P31749 1/20 0.36
POLB P06746 1/20 0.36
PDE5A O76074 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
EGFR P00533 1/20 0.35
RAF1 P04049 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
GSK3B P49841 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5499236 0.90 ADORA1 (0.62) ADORA1IGF1RMAPK1MAPK14MAPK3
SCHEMBL7301958 0.89 ADORA1 (0.66) ADORA1IGF1RMAPK1MAPK14MAPK3
SCHEMBL7303349 0.88 ADORA1 (0.65) ADORA1IGF1RMAPK1MAPK14MAPK3
SCHEMBL7292724 0.87 ADORA1 (0.64) ADORA1IGF1RMAPK1MAPK14MAPK3
SCHEMBL7300326 0.87 ADORA1 (0.64) ADORA1IGF1RMAPK1MAPK14MAPK3
SCHEMBL7301555 0.87 ADORA1 (0.64) ADORA1IGF1RMAPK1MAPK14MAPK3
SCHEMBL7303029 0.87 ADORA1 (0.64) ADORA1IGF1RMAPK1MAPK14MAPK3
SCHEMBL7290142 0.87 ADORA1 (0.64) ADORA1IGF1RMAPK1MAPK14MAPK3
SCHEMBL7292830 0.87 ADORA1 (0.64) ADORA1IGF1RMAPK1MAPK14MAPK3
SCHEMBL7301517 0.87 ADORA1 (0.64) ADORA1IGF1RMAPK1MAPK14MAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0497258-B1 Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer FUJISAWA PHARMACEUTICAL CO (JP) 2002-01-02 EP disclosed
EP-0467248-B1 Pyrazolopyridine compound and processes for preparation thereof FUJISAWA PHARMACEUTICAL CO (JP) 1998-10-28 EP disclosed
US-5338743-A Pancreatitis FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-08-16 US disclosed
US-5204346-A Cognition activators; analgesics; antidepressants; vasodilation; cardiovascular and urogential disorders; FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-04-20 US disclosed
EP-0497258-A2 Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-08-05 EP disclosed
EP-0467248-A2 Pyrazolopyridine compound and processes for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-01-22 EP disclosed